Last update July 1, 2015


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is excreted into breast milk in clinically non-significant amount.

Not effects on the infant's physical and psychomotor development at both short or long-term were found.

Variable levels of Prolactin secretion (increment or lowering), which were non-significant, were found after the use of Trazodone.

Because there is less experience published than with other drugs of the same pharmacological group, it should be preferred the use of an alternative drug that is known to be safer in the neonatal period or prematurity.


Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Trazodone is also known as

Trazodone in other languages or writings:


Trazodone belongs to this group or family:


Main tradenames from several countries containing Trazodone in its composition:


Variable Value Unit
Oral Bioavail. 65 %
Molecular weight 408 daltons
Protein Binding 89 - 95 %
VD 0.84 ± 0.16 l/Kg
Tmax 0.5 - 2 hours
T1/2 5 - 13 hours
M/P ratio 0.2 -
Theoretical Dose 0.006 - 0.017 mg/Kg/d
Relative Dose 0.1 - 0.7 %


  1. Angelini. Trazodona. Ficha técnica. 2012 Full text (in our servers)
  2. Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011 Abstract
  3. LaboPharm. Trazodone. Drug Summary. 2010 Full text (in our servers)
  4. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry. 2009 Abstract
  5. Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol. 2006 Oct;26(5):508-11. Abstract
  6. Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y. Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Abstract
  7. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med. 1991 Abstract
  8. Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol. 1986 Abstract Full text (link to original source) Full text (in our servers)
  9. Roccatagliata G, Murialdo G, Albano C, Giovale M, Zauli C, Polleri A. Neuroendocrinological and clinical data upon trazodone treatment in depressed patients. Neuropsychobiology. 1982 Abstract
  10. Rolandi E, Magnani G, Milesi GM, Barreca T. Effect of a psychoactive drug, trazodone, on prolactin secretion in man. Neuropsychobiology. 1981 Abstract
  11. Roccatagliata G, De Cecco L, Rossato P, Albano C. Trazodone intravenously administered and plasma prolactin levels. Int Pharmacopsychiatry. 1979 Abstract
  12. Mazzi C, Montanini R, Riva LP. [Action of trazodone on the secretion of pituitary hormones. Behavior of prolactin and somatotropin]. Minerva Med. 1979 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM